Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT02265510

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Sponsor: Incyte Corporation

Conditions Advanced Malignancies Metastatic Cancer Solid Tumors

Interventions Carfilzomib INCB039110 INCB050465 INCB052793 azacitidine bortezomib dexamethasone gemcitabine lenalidomide nab-paclitaxel pomalidomide

Updated 16 times since 2017 Last updated: Apr 6, 2020 Started: Sep 10, 2014 Primary completion: Feb 27, 2019 Completion: Feb 27, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Other Advanced Malignancies trials with similar outcome

Browse all Advanced Malignancies trials

This PHASE1/PHASE2 trial investigates Advanced Malignancies and Metastatic Cancer and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 16 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

16 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
May 2020 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

Status: Completed → Terminated
Oct 2019 — May 2020 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

Aug 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2019 — Jun 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2018 — May 2019 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2018 — May 2018 [monthly]

Recruiting PHASE1_PHASE2
Feb 2018 — Apr 2018 [monthly]

Recruiting PHASE1_PHASE2
May 2017 — Feb 2018 [monthly]

Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
Feb 2017 — May 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Birmingham, United States , Chicago, United States , Dallas, United States , Durham, United States , Greenville, United States , Hackensack, United States , Indianapolis, United States , Nashville, United States , New Haven, United States and 3 more locations